{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:55:20Z","timestamp":1792688120690,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,7,1]]},"DOI":"10.1001\/jamadermatol.2020.1300","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T11:02:09Z","timestamp":1589972529000},"page":"787","source":"Crossref","is-referenced-by-count":91,"title":["Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases"],"prefix":"10.1001","volume":"156","author":[{"given":"Shamarke","family":"Esse","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, United Kingdom"},{"name":"Dermatology Centre, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh J.","family":"Mason","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele C.","family":"Green","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom"},{"name":"QIMR Berghofer Medical Research Institute, Brisbane, New South Wales, Australia"},{"name":"Cancer Research UK Manchester Institute, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi200025r1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.13101","article-title":"Genetics of immune-mediated inflammatory diseases.","volume":"193","author":"David","year":"2018","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"doi200025r2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1476-4598-12-98","article-title":"Cancer risk in immune-mediated inflammatory diseases (IMID).","volume":"12","author":"Beyaert","year":"2013","journal-title":"Mol Cancer"},{"issue":"978","key":"doi200025r3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"issue":"6","key":"doi200025r4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"doi200025r5","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis.","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"9853","key":"doi200025r6","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis.","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"issue":"9853","key":"doi200025r7","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease.","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"doi200025r8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.2012.630388","article-title":"Update upon efficacy and safety of TNF-a inhibitors.","volume":"11","author":"Murdaca","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"doi200025r9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis.","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"doi200025r10","doi-asserted-by":"crossref","first-page":"j2505","DOI":"10.1136\/bmj.j2505","article-title":"Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.","volume":"357","author":"Cohen","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"doi200025r11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","article-title":"Malignancy incidence, management, and prevention in patients with rheumatoid arthritis.","volume":"4","author":"Wilton","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"10","key":"doi200025r12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents.","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"62","key":"doi200025r13","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: a balance between immunosurveillance and immune escape.","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"doi200025r14","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/bjd.17366","article-title":"Long-term safety of adalimumab in adult patients with plaque psoriasis.","volume":"180","author":"Leonardi","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200025r15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi200025r16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12891-015-0772-2","article-title":"Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.","volume":"16","author":"Buchbinder","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"doi200025r17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis.","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi200025r18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT\u2122 Registry.","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"doi200025r19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"doi200025r20","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis.","volume":"77","author":"Olsen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"doi200025r21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"doi200025r22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies.","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"3","key":"doi200025r23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update.","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"doi200025r24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"doi200025r25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review.","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi200025r26","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"issue":"2","key":"doi200025r27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/jid.2009.258","article-title":"Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma.","volume":"130","author":"Duffy","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi200025r28","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jid.2018.12.006","article-title":"Trends in melanoma incidence rates in eight susceptible populations through 2015.","volume":"139","author":"Olsen","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi200025r30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1185\/03007995.2015.1065242","article-title":"Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.","volume":"31","author":"McAuliffe","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"doi200025r31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"doi200025r32","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-a antagonists and risk of cancer in patients with inflammatory bowel disease.","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"doi200025r33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNFa inhibitor treated patients with rheumatoid arthritis and other arthritides: a follow-up study from the DANBIO Registry.","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"doi200025r34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0050-7","article-title":"Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study.","volume":"3","author":"Staples","year":"2019","journal-title":"BMC Rheumatol"},{"issue":"11","key":"doi200025r35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden.","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"9","key":"doi200025r36","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study.","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"doi200025r37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"issue":"9","key":"doi200025r38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","article-title":"Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"doi200025r39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.sapharm.2018.05.009","article-title":"The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis.","volume":"15","author":"Aladul","year":"2019","journal-title":"Res Social Adm Pharm"},{"issue":"8","key":"doi200025r40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s12325-015-0233-1","article-title":"The budget impact of biosimilar infliximab (Remsima\u00ae) for the treatment of autoimmune diseases in five European countries.","volume":"32","author":"Jha","year":"2015","journal-title":"Adv Ther"},{"key":"doi200025r41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2019.1610553","article-title":"Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.","author":"Barker","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"doi200025r42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/17474124.2019.1645595","article-title":"Anti-TNF biosimilars in Crohn\u2019s disease: a patient-centric interdisciplinary approach.","volume":"13","author":"Peyrin-Biroulet","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"doi200025r43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.adaj.2015.02.010","article-title":"The limitations of using insurance data for research.","volume":"146","author":"Hyman","year":"2015","journal-title":"J Am Dent Assoc"},{"issue":"5","key":"doi200025r44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians.","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"issue":"5","key":"doi200025r45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1067\/mjd.2001.114576","article-title":"The risk of melanoma in association with long-term exposure to PUVA.","volume":"44","author":"Stern","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"doi200025r46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi200025r29","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses coding manual [Internet]. Ottawa, Canada: The Ottawa Hospital Research Institute. Accessed June 1, 2019. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/nos_manual.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2766278\/jamadermatology_esse_2020_oi_200025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:02:25Z","timestamp":1594206145000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2766278"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.1300","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}